newsfilter
← Latest News
GlobeNewswire·

Aerpio Announces Initiation of 28-Day Phase 2 Razuprotafib Glaucoma Trial

CINCINNATI, June 24, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular...